Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue, while reporting ...

Anti-aging biotech NewLimit plans to push a liver-rejuvenating mRNA medicine into the clinic with the aid of a ...

The FDA elevated a recall of intraocular lenses currently being wrapped up by Bausch + Lomb, following increased reports of ...

Mersana Therapeutics only has eyes for Emi-Le. Seeking to extend its cash runway into mid-2026, the biotech is laying off 55% ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

The National Institutes of Health (NIH) has laid off 250 more employees, with this round of cuts hitting 50 workers at the ...

Masimo disclosed that a cyber attack on its systems has hit its manufacturing facilities, slowing production at the remote patient monitoring company. | Masimo has disclosed that a cyber attack on its ...

PTC Therapeutics reported a phase 2 win for its Novartis-partne | PTC Therapeutics reported a phase 2 win for its ...

Abbott’s rapid, blood-based test for concussions is making its sporting debut through the motorcycle racing series ...

Capricor Therapeutics saw its shares fall 13% by the end of trading Monday as its investigational cell therapy deramiocel for ...

A phase 3 trial of Aldeyra Therapeutics’ dry eye disease prospect has hit its primary endpoint, teeing the biotech to seek ...

Biomea Fusion is following through on a New Year’s resolution to become a metabolic-focused company. | Biomea Fusion is ...